广泛期小细胞肺癌内科治疗进展

Progress in the treatment of extensive-stage small cell lung cancer

广泛期小细胞肺癌预后极差,中位生存期约8～10个月,其治疗几十年来进展甚微,含铂两药的治疗方案一直是一线治疗的不二选择。几乎所有的患者都会发生复发或耐药,可选的方案十分有限,现有的治疗方式已达瓶颈,随着对小细胞肺癌分子生物学认识的深入,研究重点转向了分子靶向和免疫治疗。伴随着大批试验性药物的涌现,促进了新药物的研发,一系列药物在早期临床试验中的表现似乎打破了"小细胞肺癌是药物开发坟墓"的诅咒。这些新药主要包括抗血管生成抑制剂、免疫检查点抑制剂、抗凋亡蛋白抑制剂、抗藕联药物等,我们期待能为广泛期小细胞肺癌患者的治疗带来一丝曙光。

Extensive-stage small cell lung cancer(SCLC)remains a disease with a dismal prognosis,with median survival of approximately8?10months.There was not any breakthrough in the treatment of SCLC,and two platinum treatment options have been the first choice.Virtually all patients develop relapse or resistance,for those only have few therapy unluckily,so the existing treatment has reached the bottleneck.With a new understanding of molecular biology behavior,research has shifted to molecular targeting and immunotherapy.With the advent of a large number of experimental drugs,the development of new drugs has been promoted.The performance of a series of drugs in early clinical trials seems to have broken the curse that"small cell lung cancer is the tomb of drug development".These new drugs mainly include anti-angiogenesis inhibitors,immune checkpoint inhibitors,anti-apoptotic protein inhibitors,anti-drug drugs and so on.We are looking forward to a glimmer of hope for the treatment of patients with extensive-stage small cell lung cancer.